Advertisement

Topics

PubMed Journals Articles About "Cristal Therapeutics Present Data American Society Clinical Oncology" RSS

05:32 EDT 20th June 2019 | BioPortfolio

Cristal Therapeutics Present Data American Society Clinical Oncology PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Cristal Therapeutics Present Data American Society Clinical Oncology articles that have been published worldwide.

More Information about "Cristal Therapeutics Present Data American Society Clinical Oncology" on BioPortfolio

We have published hundreds of Cristal Therapeutics Present Data American Society Clinical Oncology news stories on BioPortfolio along with dozens of Cristal Therapeutics Present Data American Society Clinical Oncology Clinical Trials and PubMed Articles about Cristal Therapeutics Present Data American Society Clinical Oncology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cristal Therapeutics Present Data American Society Clinical Oncology Companies in our database. You can also find out about relevant Cristal Therapeutics Present Data American Society Clinical Oncology Drugs and Medications on this site too.

Showing "Cristal Therapeutics Present Data American Society Clinical Oncology" PubMed Articles 1–25 of 78,000+

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.


Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.

Comparative efficacy research performed using population registries can be subject to significant bias. There is an absence of objective data demonstrating factors that can sufficiently reduce bias and provide accurate results.

Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis.

Opioids are the primary choice for managing chronic cancer pain. However, many nonopioid therapies are currently prescribed for chronic cancer pain with little published evidence comparing their efficacy.


Insights into lymphoma from the 2018 American Society of Clinical Oncology annual meeting.

Insights into lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary.

Highlights in colorectal cancer from the 2018 American Society of Clinical Oncology annual meeting.

Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route.

Clinical Diagnosis Value of Chest X-Ray and Ultrasound in Recurrence in Patients With Favorable-Histology Wilms Tumor.

Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice?

Expanding Access to Cancer Clinical Trials for Patients With Mental Illness.

Paying Clinical Trial Participants: Legal Risks and Mitigation Strategies.

Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features.

Conceptual Model for Accrual to Cancer Clinical Trials.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible onc...

Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.

The Oncology Hospital at Home.

Laughter in Oncology Is More Common Than You Think.

Who Are the Patients in Our Clinical Trials for Cancer?

MicroRNA Dysregulation in Malignant Germ Cell Tumors: More Than a Biomarker?

Open the Gates for Treatment De-Intensification in Head and Neck Cancer.

Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia.

Phthalate Exposure From Prescription Medications and Breast Cancer Risk.

Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma.


Advertisement
Quick Search
Advertisement
Advertisement